Juniper Pharmaceuticals (JNP) Inactive 10-Q2015 Q2 Quarterly report

Filed: 4 Aug 15, 12:00am

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. freshman Avg

New words: Allergan, Australia, biopsy, biotechnology, Canada, challenging, Corporate, decline, efficacy, endometrial, endpoint, fairly, foregoing, global, heightened, intensity, linked, molecule, monitored, perspective, placement, priority, problem, proportionally, pursuit, recruitment, regular, safety, small, solving, specialty, stage, submission, successful, tenaculum, training, transvaginal, undergoing, Union, unique, view

Removed: acquire, acted, adequately, al, alleged, amenorrhea, analytic, andShu, appealed, artificially, asserted, attempt, attorney, award, birth, buccal, captionsWright, case, cervical, chose, Circuit, claim, cognizable, complaint, construction, court, deceive, defend, defraud, director, disclose, dismissal, dismissed, District, duty, enabling, entitledIn, expiration, facilitate, failure, false, futile, hypogonadism, inference, inflating, intent, July, Litigation, male, manipulate, merit, misleading, moved, NDA, omitted, ordered, plead, PREGNANT, prejudice, premature, preterm, prevention, proceeding, promulgated, putative, relief, ruled, scheduled, shortening, sought, stabilization, target, testosterone, thirty, unspecified, vigorously

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

JNP similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 32.1

Certification Pursuant to

18 U.S.C. Section 1350

as Adopted Pursuant to

Section 906 of the Sarbanes-Oxley Act of 2002

In connection with the Quarterly Report of Juniper Pharmaceuticals, Inc. (the “Company”) on Form 10-Q for the period ended June 30, 2015 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Frank C. Condella, Jr., President and Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. section 1350, as adopted pursuant to section 906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge:

(1)	The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2)	The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.

/s/ Frank C. Condella, Jr.

Frank C. Condella, Jr.

President and Chief Executive Officer

Date: August 4, 2015